Expanded indication builds on existing U.S. FDA approval of mRESVIA for adults aged 60 and older CAMBRIDGE, MA / ACCESS ...

Novavax's experimental COVID-19-influenza combination and standalone influenza vaccines generated a strong immune response in ...

After soaring to success in the early days of the COVID-19 pandemic, Moderna (NASDAQ: MRNA) experienced a reversal of fortune ...

Moderna vaulted to the forefront of biotech, becoming a major pillar of the region’s economy. But Robert F. Kennedy Jr.’s ...

The Food and Drug Administration (FDA) has approved Moderna’s next-generation mRNA COVID-19 vaccine mNexspike ®.

The main reason for the downturn in Moderna’s stock is a significant drop in the demand for its COVID-19 vaccine.

The FDA expanded the approval of Moderna’s RSV vaccine, extending the license to include more adults and giving the company a welcome win.

(HealthDay News) — The U.S. Food and Drug Administration has approved a new lower-dose vaccine for active immunization against COVID-19 caused by severe acute respiratory syndrome coronavirus 2.

US Health Secretary Robert F. Kennedy Jr.'s dismissal of a key panel that advises on immunizations policy is a significant ...

President Trump’s administration has slammed the brakes on development of messenger RNA (mRNA) vaccines, which proved their ...

Interest in what caused the coronavirus pandemic has many political dimensions today, with President Trump saying genetic ...